



Important information for users of medicines for diabetes (except insulins)

On 25 November 2024, we are changing the conditions for reimbursement of certain medicines used to treat type 2 diabetes. On the back of this page, you can see whether this will have any impact on your medicine.

Note: If your medicine is not mentioned on the back of this page, there will be no changes to your treatment, and you do not need to do anything.

If your medicine is mentioned in the **yellow list**, you may still be eligible for reimbursement if your doctor finds that you meet the new conditions for reimbursement.

If your medicine is mentioned in the **red list**, you will no longer be eligible for automatic reimbursement, but your doctor can, in special cases, apply for reimbursement on your behalf.

Talk to your doctor

If your medicine is listed on the back of this page, you must talk to your doctor about your future treatment to ensure that you will still be eligible for reimbursement after 25 November 2024. We suggest that you do so in connection with your next check-up or renew your prescription. Your doctor has also been informed about the changes.

Want to know more?

On our website you can find further information about the changes in reimbursement:

www.lmst.dk/tilskud-aendringer-diabetesmidler-non-insuliner

You can also access this information by scanning the QR code below.



Yours faithfully
The Danish Medicines Agency



IMPORTANT! If you are being treated with one or more of the following type 2 diabetes medicines, you must talk to your doctor about your future treatment before 25 November 2024.

Yellow list: If you are taking any of the following medicines, your doctor will need to assess whether you meet the new conditions for reimbursement.

Name	You meet the new conditions if:
Ozempic inj.væske, fyldt pen	<ul style="list-style-type: none">- You have type 2 diabetes and cannot take a SGLT-2 inhibitor due to side effects or very poor kidney function while also having: (1) cardiovascular or kidney disease; or (2) at least three risk factors for cardiovascular disease and poor blood sugar control with metformin.- You have type 2 diabetes and poor blood sugar control despite treatment with all relevant tablets for diabetes, including a SGLT-2 inhibitor.
Trulicity 1,5 mg, inj.væske, fyldt pen	
Rybelsus tabletter	

Red list: If you take any of the following medicines, you will generally have to switch to other medicines in order to be eligible for reimbursement in the future.

Name	Name
Glyxambi filmovertrukne tabletter	Repaglinide "Accord" tabletter
Jentadueto filmovertrukne tabletter	Repaglinide "Krka" tabletter
Komboglyze filmovertrukne tabletter	Trajenta filmovertrukne tabletter
Minodiab tabletter	Victoza inj.væske, fyldt pen
NovoNorm tabletter	Vipdomet filmovertrukne tabletter
Onglyza filmovertrukne tabletter	Vipidia 12,5 og 25 mg filmovertrukne tabletter
Qtern filmovertrukne tabletter	Vokanamet filmovertrukne tabletter
Repaglinid "Teva" tabletter	